JP Morgan Chase
BTAI icon

JP Morgan Chase’s BioXcel Therapeutics BTAI Stock Holding History

JP Morgan Chase’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63 Hold
45
– – ﹤0.01% 7570
2026
Q1 		$54 Hold
45
– – ﹤0.01% 7352
2025
Q4 		$72 Hold
45
– – ﹤0.01% 7239
2025
Q3 		$115 Hold
45
– – ﹤0.01% 7159
2025
Q2 		$81 Sell
45
-71
-61% -$118 ﹤0.01% 6863
2025
Q1 		$235 Buy
116
+33
+40% +$123 ﹤0.01% 6783
2024
Q4 		$496 Buy
83
+36
+77% +$301 ﹤0.01% 6801
2024
Q3 		$457 Hold
47
– – ﹤0.01% 6809
2024
Q2 		$959 Sell
47
-512
-92% -$17.1K ﹤0.01% 6625
2024
Q1 		$25.2K Sell
559
-235
-30% -$11.2K ﹤0.01% 6165
2023
Q4 		$37.5K Sell
794
-7
-0.9% -$389 ﹤0.01% 6090
2023
Q3 		$32.4K Sell
801
-539
-40% -$54.5K ﹤0.01% 5939
2023
Q2 		$143K Buy
1,340
+259
+24% +$86.2K ﹤0.01% 5279
2023
Q1 		$322K Buy
1,081
+356
+49% +$152K ﹤0.01% 4764
2022
Q4 		$249K Buy
725
+63
+10% +$15.2K ﹤0.01% 4923
2022
Q3 		$126K Buy
662
+13
+2% +$3.02K ﹤0.01% 5182
2022
Q2 		$137K Sell
649
-201
-24% -$42.3K ﹤0.01% 5260
2022
Q1 		$284K Buy
850
+116
+16% +$33.6K ﹤0.01% 4994
2021
Q4 		$238K Buy
734
+49
+7% +$21K ﹤0.01% 5252
2021
Q3 		$332K Buy
685
+92
+16% +$40.5K ﹤0.01% 4960
2021
Q2 		$276K Buy
593
+80
+16% +$43.6K ﹤0.01% 5069
2021
Q1 		$354K Buy
513
+150
+41% +$121K ﹤0.01% 4874
2020
Q4 		$268K Buy
363
+90
+33% +$70.1K ﹤0.01% 4701
2020
Q3 		$188K Buy
273
+50
+22% +$37.5K ﹤0.01% 4387
2020
Q2 		$189K Buy
223
+84
+60% +$54.8K ﹤0.01% 4286
2020
Q1 		$50K Sell
139
-433
-76% -$156K ﹤0.01% 4723
2019
Q4 		$134K Buy
572
+448
+361% +$45K ﹤0.01% 4808
2019
Q3 		$14K Buy
124
+20
+19% +$3.15K ﹤0.01% 5457
2019
Q2 		$18K Buy
+104
New +$17.6K ﹤0.01% 5461

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's BTAI Position: Q2 2026 in Review

JP Morgan Chase held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 45 shares worth $63. The position accounts for ﹤0.01% of the portfolio, ranked #7570.

JP Morgan Chase first reported a position in BTAI in Q2 2019 and has held it in 29 quarters since. The position peaked at $354K in Q1 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • JP Morgan Chase held 45 shares of BioXcel Therapeutics worth $63 as of Q2 2026.
  • JP Morgan Chase left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7570 holding.
  • JP Morgan Chase first reported a position in BioXcel Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's BioXcel Therapeutics position peaked at $354K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.